Quoin Pharmaceuticals, a specialty pharma company focused on rare diseases, will announce its third quarter 2026 financial results and provide a corporate update on November 5 before market open. The update will include key operational achievements and financial highlights from the quarter. Quoin is developing treatments for rare conditions like Netherton Syndrome and Peeling Skin Syndrome, with promising pipeline products QRX003 and QRX009. Investors can expect insights into the company's progress and strategic direction.
Quoin Pharmaceuticals will announce its third quarter 2026 financial results on November 5. For readers following the health sector, here is Pluang's market snapshot as of Oct 29, 2026 19:12 WIB: out of 150 priced health-sector US stocks, 91 rose and 53 fell. Baxter International Inc (BAX) rose 3.69% to USD 26.40, Vertex Pharmaceuticals (VRTX) increased 3.55% to USD 548.49, and Novartis AG (NVS) gained 3.22% to USD 161.10.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
